Sirona Biochem -- Results of Annual General Meeting

VANCOUVER, BC--(Marketwired - September 22, 2016) - Sirona Biochem Corp. (TSX VENTURE: SBM) (ZSB.F) (ZSB.DE) (the "Company") announces that all resolutions tabled at its Annual General Meeting held on September 21, 2016, were passed. The resolutions included:

• Fixing the number of directors of the Company at seven;

• Electing Geraldine Deliencourt-Godefroy, Christopher Hopton, Alex Marazzi, David Moore, Martin Gleave, Casper Bych and Howard Verrico as directors;

• Appointing MNP LLP, Chartered Accountants, as the Company's auditor for the ensuing year and authorizing the directors to set the auditor's remuneration;

• Confirming and approving the Company's existing stock option plan

The Company also announces that is has granted incentive stock options under its stock option plan to employees and consultants for the purchase of 1,600,000 common shares of the Company at a price of $0.20 per share.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.